|
KMID : 1102220220410060682
|
|
Kidney Research and Clinical Practice
2022 Volume.41 No. 6 p.682 ~ p.698
|
|
|
Advances in the management of diabetic kidney disease: beyond sodium-glucose co-transporter 2 inhibitors
|
|
Anthony T. P. Chan
Sydney C. W. Tang
|
|
|
Abstract
|
|
|
|
Progress in the treatment of diabetic kidney disease (DKD) has been modest since the early trials on renin-angiotensin-aldosterone system inhibitors (RAASis). Although sodium-glucose co-transporter 2 inhibitors (SGLT2is) have revolutionized the management of DKD by lowering proteinuria and protecting organs, other novel treatment approaches with good evidence and efficacy that can be used in conjunction with a RAASi or SGLT2i in managing DKD have emerged in the past few years. This review discusses the evidence for glucagon-like peptide-1 receptor agonist, selective mineralocorticoid receptor antagonist, and selective endothelin A receptor antagonist, emerging treatment options for DKD beyond SGLT2 inhibition.
|
|
|
KEYWORD
|
|
|
Diabetic kidney disease, Diabetic nephropathies, Glucagon-like peptide-1 receptor agonist, Non-steroidal mineralocorticoid receptor antagonist, Selective endothelin receptor antagonist, Sodium-glucose transporter 2 inhibitors
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
   
|